You are here

Cell DOI:10.1016/j.cell.2021.08.023

Proteogenomic characterization of pancreatic ductal adenocarcinoma.

Publication TypeJournal Article
Year of Publication2021
AuthorsCao, L, Huang, C, Zhou, DCui, Hu, Y, T Lih, M, Savage, SR, Krug, K, Clark, DJ, Schnaubelt, M, Chen, L, Leprevost, Fda Veiga, Eguez, RVargas, Yang, W, Pan, J, Wen, B, Dou, Y, Jiang, W, Liao, Y, Shi, Z, Terekhanova, NV, Cao, S, Lu, RJui-Hsien, Li, Y, Liu, R, Zhu, H, Ronning, P, Wu, Y, Wyczalkowski, MA, Easwaran, H, Danilova, L, Mer, ASingh, Yoo, S, Wang, JM, Liu, W, Haibe-Kains, B, Thiagarajan, M, Jewell, SD, Hostetter, G, Newton, CJ, Li, QKay, Roehrl, MH, Fenyö, D, Wang, P, Nesvizhskii, AI, Mani, DR, Omenn, GS, Boja, ES, Mesri, M, Robles, AI, Rodriguez, H, Bathe, OF, Chan, DW, Hruban, RH, Ding, L, Zhang, B, Zhang, H
Corporate AuthorsClinical Proteomic Tumor Analysis Consortium
Date Published2021 Sep 16

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient survival. Toward understanding the underlying molecular alterations that drive PDAC oncogenesis, we conducted comprehensive proteogenomic analysis of 140 pancreatic cancers, 67 normal adjacent tissues, and 9 normal pancreatic ductal tissues. Proteomic, phosphoproteomic, and glycoproteomic analyses were used to characterize proteins and their modifications. In addition, whole-genome sequencing, whole-exome sequencing, methylation, RNA sequencing (RNA-seq), and microRNA sequencing (miRNA-seq) were performed on the same tissues to facilitate an integrated proteogenomic analysis and determine the impact of genomic alterations on protein expression, signaling pathways, and post-translational modifications. To ensure robust downstream analyses, tumor neoplastic cellularity was assessed via multiple orthogonal strategies using molecular features and verified via pathological estimation of tumor cellularity based on histological review. This integrated proteogenomic characterization of PDAC will serve as a valuable resource for the community, paving the way for early detection and identification of novel therapeutic targets.


Alternate JournalCell
PubMed ID34534465
Grant ListP30 ES017885 / ES / NIEHS NIH HHS / United States